Top-News

Halozyme Therapeutics Aktie News

Aktie
WKN:  A0DLHS ISIN:  US40637H1095 US-Symbol:  HALO Branche:  Biotechnologie Land:  USA
54,54 €
+0,50 €
+0,93%
08:48:04 Uhr
Depot/Watchlist
Marktkapitalisierung *
7,67 Mrd. €
Streubesitz
-
KGV
13,94
neu: Nachhaltigkeits-Score
36 %
Index-Zuordnung
-
Weiter aufwärts? Long handeln - Jetzt mit Hebel 6,79: JU5X2J
Werbung

Halozyme Therapeutics News

28.05.25 - PR Newswire
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-​Formulated with ENHANZE® Across Multiple ...
10.05.25 - wallstreetONLINE Redaktion
Community-Rückblick: "Kann dieses verdammte Unternehmen nicht ein Mal positiv überraschen?!"
Das Hamburger Biotech-​Unternehmen Evotec hat am 06. Mai seine Zahlen zum ersten Quartal 2025 präsentiert. Die wo-​Community reagiert überwiegend enttäuscht und steht ...
06.05.25 - PR Newswire
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS PR Newswire
06.05.25 - wallstreetONLINE Redaktion
Enttäuschender Jahresauftakt: Evotec: Bitte nicht schon wieder!
Das Hamburger Biotech-​Unternehmen Evotec hat seine Zahlen zum ersten Quartal präsentiert. Die gefallen Anlegerinnen und Anlegern nicht, die Aktie fällt.Trotz der von Bristol-...
05.05.25 - PR Newswire
Halozyme to Participate in the BofA Securities 2025 Healthcare Conference
Halozyme to Participate in the BofA Securities 2025 Healthcare Conference PR Newswire
28.04.25 - PR Newswire
Halozyme to Report First Quarter 2025 Financial and Operating Results
Halozyme to Report First Quarter 2025 Financial and Operating Results PR Newswire
28.04.25 - PR Newswire
Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating ...
24.04.25 - PR Newswire
Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation
Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation PR Newswire
10.04.25 - PR Newswire
Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-​Formulated with ENHANZE® for Self-​Injection for Generalized Myasthenia Gravis and ...
09.04.25 - PR Newswire
European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility
European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, ...
07.04.25 - PR Newswire
European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-​Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-​Mutated Non-...
31.03.25 - PR Newswire
Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications
Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid ...
26.02.25 - PR Newswire
Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference
Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference PR Newswire
18.02.25 - PR Newswire
HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS
HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND ...
04.02.25 - PR Newswire
Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results
Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results PR Newswire
03.02.25 - PR Newswire
CHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
CHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-​Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-​Mutated Non-...
17.01.25 - wallstreetONLINE Redaktion
Kampf um Unabhängigkeit: Evotec: Der Chef hat das Strategie-Update angekündigt
Evotec kämpft um seine Unabhängigkeit. Vorstandschef Christian Wojczewski setzt auf eine Strategieüberprüfung und will im April erste Ergebnisse präsentieren. Was macht die ...
16.01.25 - wallstreetONLINE Redaktion
Chartanalyse: Evotec-Aktie: Es wird schon wieder kritisch!
In der Aktie von Evotec ist es vor kurzem zu einem Kaufsignal gekommen. Das hat bislang aber keine Wirkung entfalten können. Der Chartcheck!Hinter den Evotec-​Aktionären liegt ...
30.12.24 - PR Newswire
Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or ...
30.12.24 - PR Newswire
Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy
Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +0,36%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »